Brief: Synact Pharma: USPTO Issues Patent For Syntact's Resomelagon Crystal Form
04/03/2025 07:03
March 4 (Reuters) - SynAct Pharma AB SYNACT.ST: USPTO ISSUES PATENT FOR SYNTACT'S RESOMELAGON CRYSTAL FORM Source text: ID:nMFN5KrMY1 Further company coverage: SYNACT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development